| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
|
8,826 |
8,155 |
$1.02M |
| 99284 |
|
7,191 |
6,473 |
$951K |
| 99285 |
|
3,285 |
2,748 |
$313K |
| 36415 |
|
5,441 |
4,217 |
$101K |
| 87651 |
|
3,056 |
2,927 |
$84K |
| 99282 |
|
619 |
587 |
$76K |
| 70450 |
|
528 |
450 |
$74K |
| 74176 |
|
217 |
195 |
$63K |
| 80053 |
|
7,604 |
6,197 |
$52K |
| 87502 |
|
3,191 |
3,071 |
$47K |
| 71046 |
|
1,723 |
1,558 |
$34K |
| 87635 |
|
2,680 |
2,493 |
$32K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
211 |
183 |
$30K |
| 87880 |
|
415 |
397 |
$21K |
| 81001 |
|
2,798 |
2,404 |
$19K |
| 85025 |
|
7,412 |
6,022 |
$17K |
| 87086 |
|
1,433 |
1,234 |
$15K |
| 80061 |
|
1,339 |
1,263 |
$13K |
| 93005 |
|
2,187 |
1,703 |
$13K |
| 81025 |
|
986 |
906 |
$13K |
| 96374 |
|
1,416 |
1,233 |
$12K |
| 96361 |
|
678 |
556 |
$12K |
| 71045 |
|
1,642 |
1,352 |
$11K |
| 96372 |
|
1,598 |
1,272 |
$10K |
| 81003 |
|
988 |
901 |
$9K |
| 96365 |
|
450 |
352 |
$8K |
| 87634 |
|
518 |
483 |
$7K |
| 83735 |
|
1,715 |
1,434 |
$7K |
| 96375 |
|
902 |
696 |
$7K |
| 84484 |
|
1,466 |
1,072 |
$6K |
| 74177 |
|
28 |
25 |
$6K |
| 94640 |
|
392 |
268 |
$6K |
| 82550 |
|
1,220 |
916 |
$5K |
| 82553 |
|
1,053 |
799 |
$5K |
| 83690 |
|
1,045 |
908 |
$5K |
| 87186 |
|
719 |
613 |
$5K |
| 87804 |
|
519 |
301 |
$4K |
| 84443 |
|
1,963 |
1,813 |
$3K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
875 |
699 |
$3K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
867 |
734 |
$3K |
| 83880 |
|
509 |
399 |
$3K |
| 80048 |
|
567 |
467 |
$3K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,119 |
1,028 |
$3K |
| G0378 |
Hospital observation service, per hour |
29 |
25 |
$3K |
| 85610 |
|
757 |
526 |
$2K |
| 85027 |
|
598 |
498 |
$2K |
| 87798 |
|
72 |
69 |
$2K |
| 85007 |
|
524 |
436 |
$1K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
12 |
12 |
$1K |
| 80307 |
|
18 |
16 |
$1K |
| 85730 |
|
210 |
177 |
$906.55 |
| 80305 |
|
444 |
415 |
$869.25 |
| 87807 |
|
69 |
65 |
$851.80 |
| 84439 |
|
423 |
396 |
$672.15 |
| 83605 |
|
32 |
26 |
$643.15 |
| 83036 |
|
894 |
854 |
$528.90 |
| 82306 |
|
461 |
442 |
$499.90 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
195 |
186 |
$487.03 |
| 82607 |
|
317 |
297 |
$415.83 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
127 |
68 |
$326.50 |
| 87811 |
|
165 |
160 |
$304.99 |
| 82728 |
|
34 |
27 |
$197.72 |
| 94762 |
|
30 |
28 |
$157.38 |
| 73030 |
|
14 |
13 |
$127.71 |
| 80076 |
|
18 |
17 |
$116.21 |
| 83550 |
|
13 |
13 |
$6.09 |
| 83540 |
|
81 |
74 |
$4.92 |
| 82962 |
|
80 |
39 |
$0.00 |
| 82746 |
|
84 |
78 |
$0.00 |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
14 |
13 |
$0.00 |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
12 |
12 |
$0.00 |
| 96360 |
|
29 |
26 |
$0.00 |